Summary
Johnson & Johnson reported a strong first quarter for fiscal year 2024, with total sales reaching $21.4 billion, a 2.3% increase year-over-year, driven by robust operational growth of 3.9%. The company returned to profitability with net earnings of $3.3 billion, a significant improvement from a net loss of $68 million in the prior year's first quarter. This rebound was largely influenced by a substantial reduction in legal charges, particularly related to talc matters, which decreased from $6.9 billion to $2.7 billion year-over-year. The Innovative Medicine segment showed resilience with a 1.1% sales increase, supported by strong performance in Oncology and Pulmonary Hypertension, while the MedTech segment saw a 4.5% sales boost, led by growth in Cardiovascular and Orthopaedics. Despite some headwinds, including a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for key products, Johnson & Johnson demonstrated effective operational management and strategic execution. The company also continued its commitment to shareholder returns by declaring a quarterly dividend and actively repurchasing shares. The pending acquisition of Shockwave Medical, a significant move within the MedTech segment, signals a continued focus on strategic growth and portfolio enhancement.
Financial Highlights
54 data points| Revenue | $21.38B |
| Cost of Revenue | $6.51B |
| Gross Profit | $14.87B |
| SG&A Expenses | $5.26B |
| Operating Income | $3.25B |
| Interest Expense | $155.00M |
| Net Income | $3.25B |
| EPS (Basic) | $1.35 |
| EPS (Diluted) | $1.34 |
| Shares Outstanding (Basic) | 2.41B |
| Shares Outstanding (Diluted) | 2.43B |
Key Highlights
- 1Total sales increased by 2.3% to $21.4 billion, with operational growth of 3.9%, excluding currency impacts.
- 2Net earnings improved significantly to $3.3 billion from a net loss of $68 million in the prior year's quarter.
- 3The Innovative Medicine segment achieved sales of $13.6 billion, up 1.1% operationally, driven by strong performance in Oncology and Pulmonary Hypertension.
- 4The MedTech segment reported sales of $7.8 billion, a 4.5% increase, with notable growth in Cardiovascular and Orthopaedics.
- 5Earnings before taxes swung to a profit of $3.7 billion from a loss of $1.3 billion in the prior year, significantly aided by a reduction in talc litigation charges.
- 6The company announced a definitive agreement to acquire Shockwave Medical for approximately $13.1 billion, strengthening its MedTech offerings.
- 7Cash and cash equivalents increased to $25.5 billion, providing substantial liquidity for operations and strategic initiatives.